Novo Nordisk Resolves Lawsuits Against Florida Businesses Over Copycat Weight-Loss Drugs

Danish pharmaceutical giant Novo Nordisk has successfully settled lawsuits against two Florida businesses, Cosmetic Laser Professionals Med Spa and Nuvida Rx Weight Loss, accused of selling counterfeit versions of its popular weight-loss drugs Ozempic and Wegovy. The settlements, announced on February 9, 2024, mark the conclusion of a legal battle initiated by Novo Nordisk in late November, where the company filed 12 lawsuits against various entities in the United States claiming to offer semaglutide, the active ingredient in Ozempic and Wegovy.

Novo Nordisk, holding the patent on semaglutide, clarified that it does not supply the ingredient to external entities. Semaglutide, primarily used for treating type 2 diabetes, has gained popularity as an injectable weight-loss drug. The settlements with Cosmetic Laser Professionals Med Spa and Nuvida Rx Weight Loss include immediate restrictions on the businesses from falsely claiming FDA approval for their compounded drugs.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Additionally, they are barred from using Novo Nordisk trademarks or logos in their products and are prohibited from engaging in misleading advertising practices.

As part of the settlements, the defendants must prominently disclose in any advertising or marketing materials that their unapproved compounded semaglutide drugs have not undergone FDA review for safety, effectiveness, and quality. This disclosure requirement is mandated for a duration of one year. Compounded drugs, which are custom-made for individual patients, are not FDA-approved but are sought when approved medications are in short supply.

Novo Nordisk's legal action follows concerns about the quality and safety of compounded semaglutide products. The company reported testing products allegedly sold by two Florida pharmacies late last year, revealing that 33% of one sample contained "unknown impurities." Another sample was found to be impure and contained lower levels of the active ingredient than indicated, as detailed in a separate lawsuit.

The settlements underscore Novo Nordisk's commitment to protecting its intellectual property, ensuring patient safety, and maintaining the integrity of its FDA-approved medications. With the increasing demand for semaglutide for weight control, compounded drugs have become sought after, posing challenges for patients who rely on the medication for both blood sugar control and weight management.

Novo Nordisk's proactive legal approach sends a message about the company's dedication to upholding industry standards and protecting consumers from potentially unsafe medications. As the pharmaceutical landscape continues to evolve, regulatory scrutiny and legal actions against counterfeit drugs play a crucial role in maintaining public trust and ensuring the safety and efficacy of pharmaceutical products.